The growing practice of inhaling 5MeO dimethyltryptamine in Canada presents serious risks and challenging legal issues. Currently, 5meo dimethyltryptamine remains a Class I substance according to the CDSA, making its holding and distribution unlawful. While inhalation delivers the compound swiftly, it besides poses additional health threats linked